Dulabh Monga, MD
Medical Oncology · Pittsburgh, PANPI 1578564019
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $38,021 of the $44,491 with a category attached, or 85.5%. 19 manufacturers reported payments, led by AstraZeneca at 54.3% of the total. Reporting peaked in 2024 at $19,656 and has fallen 57.6% since, to $8,337 in 2025.
Across 76 payments — averaging $585.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$24K
- E.r. Squibb & Sons, L.L.C.$15K
- Amgen$4K
- Astellas Pharma US Inc$389
- Intera Oncology, Inc$316
- AbbVie$284
- plus $463 from 13 others
Across 80 payments — averaging $5034.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$317K
- Halozyme Inc$43K
- E.r. Squibb & Sons, L.L.C.$33K
- QED Therapeutics, Inc.$10K
What the payments were for
- Consulting fees$2,8756%
- Speaking & faculty fees$38,02185%
- Travel & lodging$8042%
- Food & beverage$2,2585%
- Education$5341%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $24,151 |
| E.r. Squibb & Sons, L.L.C. | 14 | $15,028 |
| Amgen | 4 | $3,861 |
| Astellas Pharma US Inc | 4 | $389 |
| Intera Oncology, Inc | 2 | $316 |
| AbbVie | 15 | $284 |
| Lilly USA, LLC | 1 | $96 |
| Ipsen Biopharmaceuticals, Inc | 1 | $95 |
| Merck | 3 | $47 |
| Eisai Inc. | 2 | $42 |
| Coherus Oncology, Inc. | 1 | $41 |
| Axsome Therapeutics, Inc. | 1 | $35 |
| Gilead | 2 | $31 |
| Bayer | 1 | $16 |
| Bristol Myers Squibb | 1 | $14 |
| Clovis Oncology, Inc. | 1 | $12 |
| Seagen Inc. | 1 | $12 |
| Pfizer | 1 | $12 |
| Genentech USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$20,477
- OPDIVO$14,801
- Vectibix$3,000
- Intera 3000 Implantable Pump$162
- Intera 3000 Hepatic Artery Infusion Pump$154
How this compares
$44,491 in reported general payments places this provider in the 85th percentile of 238 medical oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| InlytaAxitinib | 15 | $285,580 |
| AlecensaAlectinib Hcl | 11 | $208,003 |
| IbrancePalbociclib | 12 | $170,308 |
| CreonLipase/Protease/Amylase | 15 | $36,631 |
| Imatinib Mesylate | 20 | $1,965 |
| Prochlorperazine Maleate | 98 | $1,234 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 14 | $391 |
| LoperamideLoperamide Hcl | 28 | $336 |
| Ondansetron Hcl | 30 | $334 |
| Dexamethasone | 15 | $212 |
| Oxycodone Hcl | 15 | $198 |
| Mirtazapine | 22 | $188 |
| Omeprazole | 15 | $107 |
| Pantoprazole Sodium | 19 | $95 |
| Levothyroxine Sodium | 15 | $34 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerInlyta, Ibrance | $12 | $455,88827 claims |
| Genentech USA, Inc.Alecensa | $11 | $208,00311 claims |
| AbbVieCreon | $284 | $36,63115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 238 medical oncology providers in Pennsylvania.
Other medical oncology in Pittsburgh
- Adam BrufskyPittsburgh$1.3M
- John KirkwoodPittsburgh$102K
- Antoinette WozniakPittsburgh$50K
- Priya RastogiPittsburgh$27K
- Carl JunePhiladelphia$9M
- Sramila AithalBensalem$682K
- Shayma KazmiPhiladelphia$619K
- Deric SaviorWynnewood$343K
- Marcia BrosePhiladelphia$260K
- Adam CohenPhiladelphia$239K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.